The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...
The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...
Hosted on MSN15d
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide RiskMONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) ...
One recent study found that GLP-1RAs may help lower the risk for depression compared to another medication for diabetes treatment, dipeptidyl peptidase-4 inhibitors. Diabetes is a complex and ...
They do this by blocking the action of an enzyme called dipeptidyl peptidase-4 (DPP-4). This enzyme breaks down hormones that reduce blood sugar levels. By interfering with this process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback